Strategic consulting powered by trusted data, rigorous analysis, and deep industry expertise — helping you make confident commercial and deal decisions.
We support high‑impact decisions across portfolio strategy, competitive positioning, market planning, and deal evaluation — bringing clarity to complex commercial questions.
Our consulting is underpinned by Evaluate’s robust datasets and models, ensuring recommendations are grounded in consistent, transparent, and defensible evidence.
Every engagement is bespoke. We adapt our frameworks, assumptions, and outputs to your objectives, timelines, and decision context — not a one‑size‑fits‑all approach.
We focus on insight you can act on — translating analysis into clear recommendations that support alignment, negotiation, and confident decision‑making.
We provide expert consulting across four core areas — helping teams answer critical strategic, commercial, and deal‑driven questions using robust data, insight, and experience.
Support commercial strategy with bespoke market sizing and forecasting. We work with you to define assumptions, model uncertainty, and build scenarios that reflect real‑world dynamics — helping you plan with clarity and confidence.
Discover >
Navigate complex deal decisions with expert support. From opportunity assessment to valuation and scenario analysis, we provide objective insight to help structure, evaluate, and progress licensing and partnership strategies.
Discover >
Make confident portfolio decisions with strategic consulting grounded in robust evidence. We help you assess asset value, prioritise investments, and optimize portfolio mix across therapy areas and stages of development — balancing risk, opportunity, and long‑term growth.
Discover >
Stay ahead of an evolving competitive landscape with insight‑led consulting. We analyze competitors, pipelines, and strategic intent to help you anticipate market moves, pressure‑test assumptions, and identify areas of differentiation.
Discover >
Every strategic challenge is different. If you’re facing a unique commercial question or need tailored support beyond standard solutions, our consulting team will work with you to design an approach that fits your objectives, timelines, and data needs.
Our experts will help you identify the tools and insights that support your strategic, commercial, or investment priorities.
Paul leads the Evaluate’s consulting and analytics business, overseeing strategic advisory engagements across portfolio strategy, asset strategy, competitive intelligence, forecasting, valuation, and BD&L, working with clients across the global pharma and biotech ecosystem.
Paul brings extensive experience spanning academic research and life sciences consulting, supporting organizations ranging from early-stage biotech companies to large pharmaceutical corporate strategy teams. His work focuses on helping clients make evidence-based decisions across the product lifecycle, from pipeline prioritization through to commercial strategy and investment decision-making.
Mark leads client engagements focused on asset strategy, portfolio prioritization, opportunity assessment, forecasting and valuation, and development strategy across pharma and biotech portfolios. Mark brings over 25 years of biopharma and life sciences experience, having worked across academia, large pharma, and consulting roles. His background includes hands-on experience as a medicinal chemist, followed by senior analytical and advisory positions supporting strategic decision-making in R&D and commercial planning.
Ben specializes in quantitative analysis, leading projects covering buy and sell side due diligence, deal benchmarking, pipeline tracking, competitor analysis and product forecasting across a broad range of indications and markets, with an increasing focus on rare diseases. Recent work has included building prioritization models that can be used to identify in-licensing opportunities, out licensing partners, attractive indications, or technologies. Ben has authored multiple peer-reviewed journal articles and industry standard guideline documents.
As a neuroscientist, consultant and commercial leader, Kelly brings more than 16 years of experience in the life sciences sector. She partners with insights, analytics, and commercial strategy teams to transform how pharmaceutical organizations capture and operationalize market intelligence. At Evaluate, Kelly focuses on creative solutioning, bringing together life science consultants, data scientists, and subject‑matter experts to build custom intelligence programs and products that leverage the full breadth of Norstella’s assets, including gold-standard forecasting, real‑world data, market access insights, and expert journalistic intelligence. With expertise in competitive landscape analysis, tech-enabled secondary monitoring, primary research, and comprehensive conference coverage, her work supports translation of complex market signals into clear, actionable insights. Kelly holds a PhD in Neuroscience from Georgetown University and completed a postdoctoral fellowship at the National Institute of Neurological Disorders and Stroke (NINDS).
Markella brings 20 years of industry and consulting experience, with deep knowledge and expertise in oncology, rare disease and ophthalmology. She specializes in CI landscaping projects in specialty indications and has led our largest CI monitoring projects since 2020. She has led Norstella’s largest conference coverage engagements with Top 10 Pharma clients and brings on-the-ground, secondary and primary CI expertise. She holds an MBA from Baruch College and a master’s in biotechnology from Columbia University.
Hear directly from our consulting experts on how we work with clients, approach complex challenges, and deliver insight‑led support across the commercial lifecycle.
Quisque faucibus ex sapien vitae pellentesque sem placerat.
Get in touch with our team to explore the right solutions for your business.
